Nippon India Pharma Fund - Direct (G) vs SBI Gold Fund - Direct (G)
Nippon India Pharma Fund - Direct (G) vs SBI Gold Fund - Direct (G)
Nippon India Pharma Fund - Direct (G)
7.4%
SBI Gold Fund - Direct (G)
44.61%
Loading chart...
About Fund
Deutsche Bank AG
Karvy Computershare Pvt. Ltd.
Citi Bank HDFC Bank Ltd. Stock Holding Corporation of India
Computer Age Management Services Pvt. Ltd Computronics Financial Services India Ltd Datamatics Financial Software Services Ltd
Fund Details
Very High Risk
5000
9044.23
1.12
634.5023
January 1, 2013
1
Very High Risk
5000
15294.33
0.42
43.1551
January 1, 2013
1
Very High Risk
5000
9044.23
1.12
634.5023
January 1, 2013
1
Very High Risk
5000
15294.33
0.42
43.1551
January 1, 2013
1
14.01 %
19.35 %
7.4 %
23.56 %
32.57 %
44.61 %
Sailesh Raj Bhan
MBA (Finance), CFA.
Mr.Bhan is an MBA with specialization in Finance and CFA. Has over 9 Yrs. of experience in Equity Securities Research & Sequeir Investment Pvt. Ltd. for 5 years and with Emkay Share & stock Broker Pvt. Ltd. for 2 years.
Raviprakash Sharma
B.com., CA., CFA(USA)
Prior to joining SBI AMC he has worked with HDFC AMC, Citigroup Wealth Advisors India Pvt. Ltd, Kotak Securities, Times Investors Services Pvt. Ltd. and Birla Sun Life Securities.
Viral Chhadva
CFA Charter Holder from CFA Institute, USA,
Master's in Financial Management (MFM) from Jamnalal Bajaj Institute of Management Studies (JBIMS)
Mr. Viral Chhadva (Equity Dealer) joined SBIFML in December 2020. He has over 17 years of experience in financial services sector.
Prior to joining SBIFML, he was previously associated with IIFL Securities Limited (June 2008 till December 2020) and ICICI Securities Limited (June 2006 till June 2008) wherein he primarily handled execution of trades into Direct Market Access, Exchange Traded Funds and Derivatives.
